Drugs & Targets Libtayo receives FDA approval for NSCLC with high PD-L1 expression February 26, 2021Vol.47 No.08
Drugs & Targets Biocept, Protean BioDiagnostics establish research collaboration on NSCLC February 26, 2021Vol.47 No.08
Drugs & Targets IU School of Medicine researchers discover combination drug for TNBC February 26, 2021Vol.47 No.08
Drugs & Targets FDA approves Cosela to reduce bone marrow suppression caused by chemotherapy February 19, 2021Vol.47 No.07
Drugs & Targets Exact Sciences to acquire Ashion Analytics, enter research collaboration with City of Hope’s Genomics Institute, TGen February 19, 2021Vol.47 No.07
Drugs & Targets Ukoniq receives FDA accelerated approval for marginal zone lymphoma and follicular lymphoma February 12, 2021Vol.47 No.06
Drugs & Targets Breyanzi receives FDA approval for adults with relapsed or refractory large-B-cell lymphoma February 12, 2021Vol.47 No.06
Drugs & Targets Libtayo receives FDA approval as first immunotherapy for patients with advanced basal cell carcinoma February 12, 2021Vol.47 No.06
Drugs & Targets MD Anderson, Mirati Therapeutics collaborate on KRAS and solid tumor research February 12, 2021Vol.47 No.06
